BRIEF-AstraZeneca Says Kestrel Phase III Trial For Imfinzi Did Not Meet Primary Endpoint

AstraZeneca PLC: * ASTRAZENECA PLC - UPDATE ON KESTREL PHASE III TRIAL FOR IMFINZI

* ASTRAZENECA - KESTREL PHASE III TRIAL FOR ASTRAZENECA'S IMFINZI (DURVALUMAB) DID NOT MEET PRIMARY ENDPOINT OF IMPROVING OVERALL SURVIVAL * ASTRAZENECA - SAFETY AND TOLERABILITY PROFILES FOR IMFINZI AS A MONOTHERAPY AND IN COMBINATION WITH TREMELIMUMAB WERE CONSISTENT WITH PREVIOUS TRIALS

* ASTRAZENECA - COMBINATION OF IMFINZI PLUS TREMELIMUMAB DID NOT INDICATE AN OS BENEFIT IN 'ALL-COMER' PATIENTS, A SECONDARY ENDPOINT. Source text for Eikon: Further company coverage: